Ema 40 mg (Capsule (Enteric Coated))

Unit Price: ৳ 10.00 (5 x 10: ৳ 500.00)
Strip Price: ৳ 100.00

Medicine Details

Indications

  • Relief from chronic heartburn symptoms
  • Healing of erosive esophagitis
  • Maintenance of healing of erosive esophagitis
  • Eradication of Helicobacter pylori infection
  • Treatment of Zollinger-Ellison Syndrome
  • Management of Acid-related Dyspepsia
  • Treatment of Duodenal and Gastric ulcers

Pharmacology

  • Proton pump inhibitor
  • Suppression of gastric acid secretion
  • Specific inhibition of the H+/K+-ATPase
  • Single optical isomer providing better acid control
  • Enteric-coated pellet formulation
  • Metabolized in the liver by CYP enzymes
  • Extensive protein binding
  • Plasma elimination half-life of approximately 1-1.5 hours

Dosage

  • Oral dosage form
  • IV injection or IV infusion
  • Different dosages for specific indications
  • Adult and pediatric dosage specifications
  • Dosage adjustments for hepatic insufficiency

Administration

  • Instructions for tablet or capsule intake
  • Guidelines for oral suspension
  • Preparation and administration of IV injection solution

Interaction

  • Metabolism by CYP2C19 and CYP3A4
  • Potential interference with CYP2C19 substrates
  • Possible impact on absorption of drugs affected by gastric pH
  • Drug interaction studies with other medications

Contraindications

  • Hypersensitivity to any of the formulation

Side effects

  • Frequently occurring adverse events
  • Headache
  • Diarrhoea
  • Nausea
  • Flatulence
  • Abdominal pain
  • Constipation
  • Dry mouth

Pregnancy lactation

  • No adequate and well-controlled studies in pregnant women
  • No teratogenic effects observed in animal studies
  • Recommendation to discontinue breast-feeding if essential

Precautions warnings

  • Symptomatic response does not exclude the presence of gastric malignancy
  • Instructions for patients with difficulty swallowing capsules
  • Usage of antacids
  • Information for special patient groups (pediatric, geriatric, hepatic and renal insufficiency)

Use in special populations

  • Safety and effectiveness in paediatric patients not established
  • No overall differences in safety and efficacy in geriatric population
  • No dosage adjustment recommended for mild to moderate hepatic insufficiency
  • Pharmacokinetics not expected to be altered in renal impairment

Overdose effects

  • Major signs of acute toxicity
  • Symptomatic and supportive treatment recommended
  • No specific antidote known

Storage conditions

  • Recommended storage temperature and conditions

Chemical structure

  • Molecular formula
  • Chemical structure diagram

Commonly asked questions

  • Information about the medication's uses and side effects
  • Guidance for pregnant or breastfeeding individuals
  • Duration for the medication to take effect
  • Quick tips for usage

Related Brands